Page 15 - Sci Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference USA - English Share this article Share this article HOLON, Israel, March 8, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31 st Annual Healthcare Conference (virtual), on Tuesday, March 16, 2021 at 10:40 AM ET. A live webcast of the presentation will be available on Compugen's website. A replay will be available after the presentation ends. Abou...

DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin Athenex, Inc.February 18, 2021 GMT Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea. PharmaEssentia Expands Tirbanibulin Partnership by Adding Japan and South Korea to Already Licensed Territories of Taiwan, Singapore, and Malaysia Athenex’s Existing Partners Include Almirall, S.A., in the United States, Europe, ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy ... Athenex, Inc.February 11, 2021 GMT The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, developed by Athenex, received FDA approval in December 2020 Across two large Phase III randomized control...

RALEIGH, NC / ACCESSWIRE / February 10, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that its Chief Executive Officer